Skip to main content
. 2015 Jan 1;5(1):43–61. doi: 10.7150/thno.10350

Figure 6.

Figure 6

Inhibition of the production of targeting ligand specific antibodies after systemic delivery of theranostic IONPs carrying doxorubicin. A. ELISA analysis of mouse serum samples obtained from 4T1 tumor bearing mice after systemic delivery of 200 pmol of mATF-IONPs or mATF-IONP-Dox nanoparticles (left) via tail or 200 pmol of ScFvEGFR-IONPs, ScFvEGFR-IONP-Dox, ScFvEGFR-PEG-IONPs, ScFvEGFR-PEG-IONP-Dox nanoparticles (right). Mouse IgG antibody was measured. n=3 mice/group. B. Cell Proliferation assay of the RAW 264.7 mouse macrophage cell line or primary dendritic cells following treatment with 50 nM of Dox or Dox equivalent of IONPs for 48 hours. Crystal Violet Cell Proliferation assay was used for determining the percentage of cell growth inhibition. Fluorescence microscopy detected a higher level of Dox fluorescence (red) in the cells treated with 100 nM of ATF-IONP-Dox for 24 hours than that of the equal concentration of free Dox treatment. Prussian blue staining was used to determine IONP uptake as well as the cell density after the treatment.